Introduction
Over 150 y ago, Virchow recognized the inflammatory component of atherosclerosis, and commented on it in his writings. 1 It has just been within the last 10 y, however, that we have rediscovered and clearly identified the important association between atherosclerosis and the wide variety of activities that are components of what might be considered 'inflammation'. Many areas of research have contributed to this new emphasis, including molecular anatomy and histology, biochemistry, cell biology, and molecular biology/genetics. Also, and in particular, molecular epidemiology has played an important role; this is the area I will emphasize in this brief review. From a population biology standpoint, two important findings preceded this new era, and laid the groundwork for inflammation as an important component of atherosclerosis and heart disease. The first was the work of Meade et al 2 and others in the 1980s identifying fibrinogen as a risk marker of approximately equal strength to that of cholesterol. Not long before, thrombosis had been identified as the proximate cause of myocardial infarctions (MI), so the fibrinogen findings were initially interpreted in the context of fibrinogen's role as a coagulation factor. However, fibrinogen was a known acute-phase protein, and the possibility that higher values were a marker of underlying inflammation was not completely overlooked. The second important observation was that higher plasma levels of acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A were associated with increased risk of poor prognosis in those with established cardiovascular disease. 3 This work extended the fibrinogen findings and emphasized the inflammatory nature of these markers, since these were all acute-phase proteins. These two findings were followed by a large number of epidemiological studies in otherwise healthy individuals, many of which focused on CRP, demonstrating that even within the so-called 'normal range', higher values of CRP compared to lower values indicated increased cardiovascular disease (CVD) risk. 4 Throughout this research, however, the essential question remained: did the levels of these plasma proteins simply reflect the underlying pathophysiology, or did these proteins actually participate in the disease process? A third position existed, which is that both of the above are correct. These possibilities are illustrated in Figure 1 . We have consistently supported the third position, since there is a considerable body of work to support each side of the initial question. 5 We will return to this issue later in the review.
Finally, what do we mean by the term inflammation? In this context, we are not discussing the process characterized classically by redness, swelling, heat, and pain. Rather, we are discussing a type of 'microinflammation', possibly localized to discrete spots in the vasculature, which is mediated by the same cytokines and effector molecules as the classic process but differs markedly in degree. Using CRP as an example, prior to the last decade, CRP levels were considered to be either 'normal' (o10 mg/l) or 'abnormal' (410 mg/l). CRP has a large dynamic range (B1000-fold), and most assays in use at that time did not even return a value below 10 mg/l, since the distribution of values below this level was not considered informative. Owing to the sensitive assays developed by Pepys' lab (a radioimmunoassay) and our lab (an ELISA), 6 we now know that virtually all of the risk prediction contained in the CRP distribution is within the 'normal range', that is, below 5 mg/l. It is important to note that while the term 'high sensitivity CRP', or 'hs-CRP', has come into use for assays with enough sensitivity to measure CRP levels o10 mg/l, there is no biochemical difference between CRP and hs-CRP.
CRP as a marker of inflammation
In recent years, studies of inflammation and CVD risk have focused predominantly on CRP. The correlates of CRP have been described in detail by us and others. Essentially, the major correlates of CRP levels in a healthy population are: (a) the components of the metabolic syndrome, especially adiposity; (b) diabetes status; (c) coagulation activity; and (d) smoking status. Other correlates are weaker, including HDL-cholesterol levels (negative association), sex (women tend to have higher values than men), and measures of atherosclerotic heart disease such as ultrasonographic estimates of carotid artery wall thickness and ECG abnormalities. In particular, CRP is not strongly associated with the newest measure of subclinical atherosclerosis, coronary calcification. In postmenopausal women, estrogen use is associated with B2-fold higher values, and estrogen has been shown to increase CRP. The first study of CRP and CVD risk in otherwise healthy people was done in the MRFIT cohort as a nested casecontrol study. CRP was an independent risk factor for future CVD events, especially in MRFIT smokers. This was followed up by nested case-control studies in the Cardiovascular Health Study, the Rural Health Promotion Project, and the Physician Health Study. Many studies have now been done in the US and elsewhere, both nested case-control studies and cohort studies, which have yielded consistent results: in middle aged men and women, CRP is a CVD risk factor that is independent of other known CVD risk factors. As was the case for fibrinogen in the original Northwick Park Heart Study findings, this inflammation marker is approximately as predictive as plasma lipid levels, and in the recent Women's Health Study, was actually a stronger predictor that LDL-cholesterol level. 7 One of the key correlates of CRP is adiposity, especially visceral adiposity. Body fat has received renewed attention recently as a CVD risk factor since this tissue has been recognized as a key site for proinflammatory cytokine production. 8 It is likely that increased chronic inflammation is one of the ways that visceral adiposity manifests its proatherosclerotic effects. Visceral fat is also a major site for the production of the key fibrinolysis regulator, plasminogen activator inhibitor-1 (PAI-1). This has been proposed as another mechanism by which body fat imposes atherothrombotic risk. Several investigators have suggested that CRP might be useful clinically in CVD risk assessment, along with plasma lipid levels. CRP levels are associated with most of the major components of the Framingham risk score, such as diabetes, obesity, hypertension, sex, and smoking. Therefore, in some ways, CRP may be an integrated reflection of the damage caused by these components. While CRP may add to the Framingham score in some populations, it may have only moderate added value in others. In any population, CRP may prove useful in those with moderate risk, where a low CRP value might suggest a conservative approach, and a high CRP might suggest a more aggressive approach. Also, there are difficulties with using the Framingham score, such as its complexity, which have limited the use of this method. It may be time to consider a simple, laboratory-based risk score Figure 1 Complex interplay of atherothrombotic disease with plasma markers of CVD risk: a positive feed-back pathway. This figure illustrates three possible ways of looking at the relation of inflammation mediators and markers to atherothrombotic disease. We propose that the third model is most likely, that is, that vascular disease is in fact an inflammatory process, and that markers of inflammation reflect this underlying process, but that these markers also participate in the process, making it worse. This pathophysiological participation is modulated by an individual's genetic architecture, nonvascular inflammatory burden, and ability to produce proinflammatory responses in cells such as adipocytes and monocytes.
(eg, CRP, LDL-, and HDL-cholesterol), which would contain much of the information in the Framingham score, but be more easily and more consistently applied.
Other markers of inflammation
As mentioned above, a number of plasma molecules have been studied recently, and are proposed as new risk markers. A simplified framework is offered in Table 1 . All of the markers mentioned in this table, as well as others, have either been associated with prevalent CVD, used to predict future CVD events, or both. Within this framework, CRP is seen as just one of a number of plasma markers whose levels reflect the many aspects of low-level, chronic inflammation. While each of these markers may be seen as a reflection of underlying inflammation, for each there is also one or several plausible scenarios which puts it in the causal pathway. This phenotype discovery work, whereby research continues to uncover new plasma markers of the atherothrombotic disease process, is important because it leads to a more complete understanding of the relevant mechanisms and the discovery of new mechanisms in atherothrombosis.
However, these findings also beg the question: which of these markers is most useful in clinical CVD risk assessment? HDL-cholesterol, while consistently negatively associated with inflammation, probably plays a bigger role in lipid metabolism. Fibrinogen and CRP have both been used in many studies, and yield about the same level of information. 4 The others have been studied to a lesser degree. Of CRP and fibrinogen, we have argued that CRP is probably the superior analyte based on technical reasons such as standardization, ease of the assay, reproducibility, etc.
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Consistency of association with CVD over time
The majority of the data that are currently available in the literature concerning inflammation and CVD risk assessment refer to middle-aged men and women, as reviewed above. However, there are some data to support the position that inflammation is associated with atherosclerotic disease in both older people and younger people. As part of the longitudinal epidemiology study called the Cardiovascular Health Study (CHS; 5888 men and women 464 y at baseline), we reported that both CRP and fibrinogen were significant, independent CVD risk factors in the elderly. We have also observed this for the elderly Japanese American men in the Honolulu Heart Program (HHP). Also in both the CHS and the HHP, and the Iowa 65 þ Rural Health Study, CRP and fibrinogen predicted CVD-and all-cause mortality. Therefore, it is clear that inflammation markers are associated with both fatal and nonfatal CVD events in the elderly.
In the young, there is less information available. Eventbased population data are difficult to obtain due to the necessarily long follow-up periods. Cross-sectional data, however, can be obtained. In otherwise healthy young adults (18-28 y) entered in the CARDIA study of CVD risk factors, fibrinogen levels were associated with most of the traditional CVD risk factors, suggesting a pattern that begins at early age. In similar aged individuals with type I diabetes, CRP levels were correlated with both mean and maximum carotid wall thickness; results were similar although less strong in nondiabetic controls. In 19-39 y-old subjects with childhood-onset chronic renal failure, compared to controls, there was considerable evidence of atherosclerotic disease such as increased carotid wall thickness and coronary calcification. CRP was strongly correlated to the degree of arterial disease in these subjects.
In even younger subjects, increased inflammatory marker levels have been associated with obesity and various indices of fat deposition in children, 10 while lower values have been associated with higher physical activity status and increased exercise. 11 In a group of young people, average age 10 y, CRP levels were shown to be strongly associated with endothelial function as estimated by flow-mediated brachial artery dilatation.
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Association with different pathology over time
The nature of the underlying CVD in people changes with age, as does the nature of the association of inflammation with CVD events. For example, in white men dying sudden cardiac deaths in their 4th and 5th decades, 50-70% present at autopsy with acute thrombosis, while this number drops to less than a third by the 7th decade, with a much greater percentage being stable plaque-based coronary deaths. 13 This change has implications for the use of a risk marker such as CRP in different aged populations. In younger and/or healthier people, where plaque rupture and thrombosis predominate as the causes of fatal coronary events, CRP has long-term prediction. For example, in the Physicians Health Study, elevated baseline CRP predicted MI equally strongly in the first 2 y follow-up period (0-2 y), in the next 2 y period (3-4 y), and so on out to 8 y. 14 We identified a similar finding in the Honolulu Heart Program cohort, with up to 15 y of follow-up. However, when used to predict CVD mortality in the elderly, where stable-plaque-mediated coronary deaths predominate, CRP and fibrinogen exhibited a marked interaction with time-to-event from baseline; that is, these markers were much stronger predictors of fatal CVD deaths when the event occurred closer to the baseline (N Jenny, manuscript in preparation). We have termed this 'proximate pathophysiology' to indicate the sensitivity of inflammatory markers to changes in the underlying disease process that portend soon-to-occur major events. While it would be interesting to examine the relationship of risk markers to atherosclerosis in the very young, this is not yet possible in humans. However, the mouse offers a model of early atherosclerosis, and inflammation is clearly involved in the earliest stages. In a set of experiments in C57/ Bl6 mice (both wild type and apo EÀ/À), we have demonstrated that weekly injections of Interleukin-6Fenough to generate a low-level chronic inflammatory responseFcaused a 2-5-fold increase in atherosclerotic lesions. 15 Further investigation has suggested that this is due to the role of IL-6 in T-cell differentiation, and the generation of TH1T helper cells. These cells appear to be critical in the development of early atherosclerosis in mice. Work is underway to determine if evidence can be gathered to support a similar role in humans.
A role for inflammation in early atherosclerosis, and results in younger, healthier middle-aged populations have raised the hypothesis that CRP (and other inflammation markers) are mostly sensitive to the development of lipidrich, mechanically unstable plaques, so-called 'vulnerable plaques.' To explore this hypothesis, we collaborated with Virmani and co-workers 16 at the Armed Forces Institute for Pathology, measuring CRP in post-mortem serum samples from subjects on whom autopsies had been performed and the type of lesion was well described. The results indicated that CRP was equally elevated in those who died from either thrombosis with vulnerable plaque rupture or fibrous/calcified plaque erosion, or stable plaque with no thrombosis. It would appear that inflammation is not particularly associated with the development of vulnerable plaques.
Hypercoagulable state that predisposes to CVD?
The pioneering molecular epidemiology of Meade et al, 2 at the Northwick Park Heart Study suggested that a pre-existing hypercoagulable state might be present in those most at risk for myocardial infarction and CVD death. However, ensuing research has provided little support for this as a general condition. It does not appear that elevations in factor VIIc levels are a major risk factor, 17 as originally proposed; and results for factor VIII are probably best interpreted as supporting inflammation rather than hypercoagulability. Ddimer is an integrated marker of coagulant and subsequent fibrinolytic activity; levels do not predict early calcification in younger people (Jacobs, manuscript in preparation), and were not associated with incident events in a healthy middle-aged population such as the Physician's health Study. 18 As the population under study has greater atherosclerotic burden, this marker does start to predict events: D-dimer levels were predictive in a study of men with peripheral vascular disease, and in studies of older middle-aged men with mixed health status. 19 In the elderly cohort of CHS, D-dimer, as well as the marker of plasmin activation, Plasmin-AntiPlasmin Complex, were strongly predictive of events. 20 A meta-analysis demonstrated moderate risk prediction for D-dimer. 19 The best interpretation of these data is that D-dimer reflects the degree of atherosclerosis and vascular damage present, not a preexisting hypercoagulable state. This is supported by the findings of Lowe et al, 21 where D-dimer predicted future ischemic events, but other markers of procoagulant activity such as prothrombin fragment F1 þ 2 and Thrombin-AntiThrombin Complex (thrombin generation), and factor VIIc (factor VII activation, at least partly) did not. We also have some clues about the possible role of hypercoagulability from genetic studies. There have been clear and compelling associations between venous thrombosis and genetic states such as protein C deficiency (lack of an anticoagulant), factor V Leiden (a procoagulant that is resistant to inactivation), and prothrombin 20210 (increased procoagulant zymogen levels). The presence of genetic variants that result in either increased procoagulation, or reduced anticoagulation lead to increased risk for venous thrombosis. However, none of these variants are risk factors for arterial disease. The exception concerns the atypical arterial thrombosis occurring in otherwise healthy younger women. The preponderance of data again indicates that there are no compelling data supporting the importance of a pre-existing hypercoagulable state as a major risk factor for atherothrombotic disease.
Association not specific for CVD
One of the emerging issues concerning inflammation and risk prediction is that these markers are not specific for cardiovascular disease. In fact, in addition to atherothrombotic disease, markers of inflammation are associated with the presence of, or predictive of the future occurrence of, virtually all the chronic diseases of older age including heart failure, type II diabetes, cancer, frailty, cognitive decline and dementia, and osteoporosis as well as all-cause mortality.
These findings raise a number of questions, such as:
is inflammation playing a causal role in all the chronic diseases of old age?
if 'yes', what does this mean with respect to the independence of these diseases? is this at least partly the explanation for some of the 'clustering' of diseases such as is seen with type II diabetes and cardiovascular disease? what are the implications for using such markers in disease prediction and global risk assessment?
As the world population ages, answers to these questions and others will become even more critical. Increased research in these areas is needed.
Are markers in the causal pathway?
Originally, there was a question as to whether markers of inflammation simply reflected the underlying pathology, or in fact participated in the progression of the atherothrombotic disease. More recently, as discussed above and illustrated in Figure 1 , the notion that both of these positions are correct has become generally accepted. 5 The evidence to support the causal pathway model comes from several general areas: laboratory experimentation, animal models, and genetic studies. For example, a partial list of possible mechanisms directly linking CRP and fibrinogen to the atherothrombotic process is given in Table 2 . These mechanisms have been identified through lab experimentation, including histological approaches, and provide considerable indirect support for direct mechanisms for these two factors. In addition, animal model studies can provide some information. For example, as mentioned above, the increase in atherosclerotic burden generated by weekly IL-6 injection supports a direct role for IL-6 and/or other proteins whose levels are influenced by IL-6 in early atherosclerosis. In contrast, the lack of effect on atherosclerosis of knocking out the fibrinogen gene does not support a role for fibrinogen in early atherosclerosis.
Finally, genetic epidemiological studies can provide some information in this area as well, since they are not subject to the issues of confounding that can complicate the interpretation of phenotypic data. For example, fibrinogen levels are higher in older men and women with greater atherosclerotic burden. 22 Recent studies from our laboratory as part of the Cardiovascular Health Study have demonstrated that the À455 variant in the fibrinogen gene associated with higher fibrinogen levels (Z Tang, manuscript in preparation) is also associated with greater atherosclerotic burden in older people, supporting data obtained by others. Extending this, we have demonstrated that the À174 C allele of the IL-6 gene, associated with higher IL-6, CRP, and fibrinogen levels, is also associated with the lifetime development of atherosclerosis. 23 These data suggest that fibrinogen itself and possible other markers of inflammation are in the causal pathway, since forms of these genes associated with higher levels of these proteins are more frequent in older people with greater amounts of atherosclerosis compared to those with little atherosclerosis. While there is much work to be done, the bulk of the data available to date supports the position that at least some of blood markers/mediators of inflammation are in fact in the causal pathway of the atherothrombotic process.
Role of therapeutics
With the growing body of knowledge about inflammation and vascular disease (and other diseases) comes the desire to affect the process in a positive way through therapeutics. In fact, the ability to affect atherothrombosis via medications has been supported by a wide variety of studies involving a number of different therapeutics. Some of the first data in this area concerned aspirin. In the Physicians Health Study, aspirin therapy was shown to be associated with an important reduction in first MI in healthy younger middleaged men. Later analyses, after CRP values were obtained, showed that the benefit from aspirin increased with higher CRP levels, independent of lipid level, 14 suggesting an antiinflammatory effect.
Fibrates are a class of drugs that act as PPAR-a agonists, and in general lower triglycerides via activation of fatty acid metabolism and raise HDL-cholesterol. 24 Fibrates also lower fibrinogen by decreasing the ability of proinflammatory cytokines such as IL-1b to activate the inflammatory cytokine cascade. The fibrinogen effect has been proposed to be a major part of fibrate-mediated CVD risk reduction.
Statins also demonstrate beneficial effects on lipoproteins (targeted more to LDL-cholesterol decline than triglyceride decline), but do not affect fibrinogen. 25 However, statins also lower CRP and have an apparent anti-inflammatory effect. supporting the hypothesis that there may be important benefits to reducing chronic inflammation. These data, and others, have supported the concept of pleiotropic effects of drugs like aspirin, the statins, and the fibrates. Research over the next several years should help us understand in more detail the potential for anti-inflammatory therapy in primary and secondary risk reduction.
Conclusions
The last 10 y have seen an enormous surge in research focused on inflammation and heart disease. In parallel, inflammation (used as a term to represent a broad array of response systems) has become a topic of interest in a number of different areas of chronic disease including type II diabetes, cognitive decline and frailty, among others. These discoveries are opening up many new opportunities for risk assessment and for therapeutics. These will be increasingly important as the population continues to age.
